Clinical Trials and Basic Research: Defining Mechanisms and Improving Treatment in Connective Tissue Disease

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2007 Sep 15

PMID 17767739

Authors

Lewis J Rubin

Carol M Black

Christopher P Denton

James R Seibold

Affiliations

Soon will be listed here.

Abstract

Despite advances in elucidating the pathogenic factors responsible for its development, systemic sclerosis remains complex and poorly understood, and treatment options are limited. Multidisciplinary collaborative efforts are needed to better characterize clinical and prognostic parameters and to design and implement large-scale clinical trials in well defined populations with therapies that target potential disease modulators.

References

Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M . Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol. 2000; 27(1):149-54. View

Steen V, Medsger Jr T . Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000; 133(8):600-3. DOI: 10.7326/0003-4819-133-8-200010170-00010. View

Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358(9288):1119-23. DOI: 10.1016/S0140-6736(01)06250-X. View

Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346(12):896-903. DOI: 10.1056/NEJMoa012212. View

Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R . Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?. J Rheumatol. 1994; 21(10):1838-44. View

Korn J, Mayes M, Cerinic M, Rainisio M, Pope J, Hachulla E . Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50(12):3985-93. DOI: 10.1002/art.20676. View

Carulli M, Ong V, Ponticos M, Shiwen X, Abraham D, Black C . Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005; 52(12):3772-82. DOI: 10.1002/art.21396. View

Newby A . Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2005; 69(3):614-24. DOI: 10.1016/j.cardiores.2005.08.002. View

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View

10.

Maruotti N, Cantatore F, Crivellato E, Vacca A, Ribatti D . Angiogenesis in rheumatoid arthritis. Histol Histopathol. 2006; 21(5):557-66. DOI: 10.14670/HH-21.557. View

11.

Nakerakanti S, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M . Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem. 2006; 281(35):25259-69. DOI: 10.1074/jbc.M600466200. View

12.

Denton C, Humbert M, Rubin L, Black C . Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006; 65(10):1336-40. PMC: 1798307. DOI: 10.1136/ard.2005.048967. View

13.

Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C . Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006; 54(9):3034-42. DOI: 10.1002/art.22036. View

14.

Distler O, Behrens F, Huscher D, Foeldvari I, Zink A, Nash P . Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford). 2006; 45(12):1455-7. DOI: 10.1093/rheumatology/kel273. View

15.

Buch M, Denton C, Furst D, Guillevin L, Rubin L, Wells A . Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2006; 66(2):169-73. PMC: 1798506. DOI: 10.1136/ard.2006.054866. View

16.

Abraham D, Distler O . How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther. 2007; 9 Suppl 2:S2. PMC: 2072886. DOI: 10.1186/ar2186. View

17.

Denton C . Therapeutic targets in systemic sclerosis. Arthritis Res Ther. 2007; 9 Suppl 2:S6. PMC: 2072882. DOI: 10.1186/ar2190. View